Randomised trial comparing doxorubicin, paclitaxel (AT), versus paclitaxel (T), as second line therapy for advanced ovarian cancer (AOC) patients in early progression after platinum-based chemotherapy.
ANNALS OF ONCOLOGY（2000）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要